DOCSLIB.ORG

Lung Cancer—Non-Small Cell Metastatic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lung Cancer—Non-Small Cell Metastatic LUNG CANCER—NON-SMALL CELL METASTATIC 9000 Oral Abstract Session, Mon, 8:00 AM-11:00 AM RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Chao-Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin-Yuan Shih, Kwok Hung Au, Denis Moro-Sibilot, Sotaro Enatsu, Annamaria H. Zimmermann, Bente Frimodt-Moller, Carla M. Visseren Grul, Martin Reck; Kindai University Hospital, Osaka, Japan; David Geffen School of Medicine, University of California/TRIO-US Network, Los Angeles, CA; National Kyushu Cancer Center, Fukuoka, Japan; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Hospital 12 de Octubre, Madrid, Spain; Taipei Veterans General Hospital, Taipei, Taiwan; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Oncology, University of Turin, Orbassano, Italy; Institut Catala ` d’Oncologia, L’Hospitalet, Barcelona, Spain; Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Queen Elizabeth Hospital, Kowloon, China; Service Hospitalier Universitaire Pneumologie Physiologie Poleˆ Thorax et Vaisseaux Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; Lilly Research Laboratories Japan, Kobe- shi, Japan; Eli Lilly & Co., Indianapolis, IN; Eli Lilly and Company, Copenhagen, Denmark; Lilly Oncology Europe, Utrecht, Netherlands; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) evaluated efficacy and safety of ERL, an EGFR TKI standard-of-care, plus RAM, a human IgG1 VEGFR2 antagonist, or PL in 1L EGFRm metastatic NSCLC. Methods: Eligibility included untreated metastatic NSCLC pts with Exon 19 deletion (del) or L858R and no CNS metastasis. Randomized (1:1) pts received ERL (150 mg/day) + RAM (10 mg/kg q2w) or ERL + PL, stratified by gender, geographic region (East Asia v other), EGFRm type (Ex19del v L858R) and EGFR testing method (Therascreen/Cobas v other). The primary endpoint was Investigator assessed progression free survival (PFS). Other objectives included ORR, DoR, PFS2, OS, safety, and plasma T790M mutation (Guardant NGS). Results: 449 pts were randomized characteristics were balanced between treatment arms: Asian 77%, Females 63%, Ex19del 54%. RAM + ERL significantly prolonged PFS, DoR, and PFS2 (Table). Grade .=3 TEAEs were greater with RAM (72%) v PL (54%), largely driven by hypertension (24 v 5%, no Gr4); with 1 treatment related on study death (hemothorax) in RAM v 0 PL. EGFR T790M+ rates at progression are forthcoming. Conclusion: RAM + ERL led to superior PFS in 1L EGFRm metastatic NSCLC. Safety was consistent with the established safety profiles of the individual compounds. Clinical trial information: NCT02411448. RAM + ERL (n=224) PL + ERL (n=225) HR (95% CI) p-value PFS 0.591 (0.461 – 0.760) ,0.0001 Median, months (95% CI) 19.4 (15.4 – 21.6) 12.4 (11.0 – 13.5) Censoring rate 46% 30% ORR, % (95% CI) 76.3 (70.8 – 81.9) 74.7 (69.0 – 80.3) 0.7413 Number of responders 171 168 DoR** 0.619 (0.477 – 0.805)* 0.0003* Median, months (95% CI) 18.0 (13.9 – 19.8) 11.1 (9.7 – 12.3) Censoring rate 41% 24% PFS2 0.690 (0.490 – 0.972) 0.0325 Median, months (95% CI) NR NR Censoring rate 73% 65% Interim OS 0.832 (0.532 – 1.303) 0.4209 Median, months (95% CI) NR NR Censoring rate 83% 81% Median follow-up: 20.7 months NR, not reached * unstratified **Ns are based on number of responders from the ITT population © 2019 American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information. LUNG CANCER—NON-SMALL CELL METASTATIC 9001 Oral Abstract Session, Mon, 8:00 AM-11:00 AM Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C). Vanita Noronha, Amit Joshi, Vijay Maruti Patil, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajiv Kumar, Sucheta More, Supriya Goud, Nandkumar Kadam, Nilesh Daware, Srushti Shah, Akanksha Yadav, Amit Dutt, Vaishakhi Trivedi, Vichitra Behel, Shripad Dinanath Banavali, Kumar Prabhash; Tata Memorial Centre, Mumbai, India; Tata Memorial Hospital, Mumbai, India; Gunvati J Kapoor Medical Relief Charitable Foundation, Mumbai, India; Tata Memorial Center, Mumbai, India; Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed-carboplatin to oral TKI would improve outcomes. Methods: Phase III randomized trial in advanced chemotherapy-na¨ıve NSCLC harboring EGFR sensitizing mutation (exon 19, 21 or 18) with performance status (PS) 0 to 2 planned for palliative therapy. Patients were stratified for PS and EGFR mutation and randomly assigned (computer-generated randomization by independent biostatistician) 1:1 to gefitinib 250 mg orally daily (gef) or gefitinib 250 mg orally daily with pemetrexed 500 mg/m2 IV and carboplatin AUC 5 IV every 3 weeks for 4 cycles, followed by maintenance pemetrexed 500 mg/m2 IVevery3weeks(gef+C). Restaging was every 2 to 3 mths; therapy continued until progression or intolerable toxicity. Primary end point was progression-free survival (PFS); secondary end points included overall survival (OS), toxicity and response rate. Survival endpoints were assessed in the intention-to-treat population. Results: Between Aug 2016 and Aug 2018, 350 patients were randomly assigned to gef (n = 177) and gef+C (n = 173). Median age was 54 yrs, 48% were females, 84% never-smokers, 21% were PS 2 and 18% had brain metastases. Median follow-up in surviving patients was 17 months (range, 7 to 30). Radiologic response rates were 81% and 69% in gef+C and gef respectively, P = 0.012. 234 patients (67%) have had events for PFS, 98 in gef+C and 136 in gef. Estimated median PFS was significantly longer with gef+C than gef (16 months, [95% CI, 13.7 to 18.3] vs. 8 months [95% CI, 7.1 to 8.9]; hazard ratio for disease progression or death, 0.5; 95% CI, 0.39 to 0.65; P , 0.001). 120 patients (34%) have died, 42 in gef+C and 78 in gef. Estimated median OS was significantly longer with gef+C than gef (not reached vs. 18 months [95% CI, 14.28 to 21.72]; hazard ratio for death, 0.45; 95% CI, 0.31 to 0.66; P , 0.001). Clinically relevant $ grade 3 toxicities occurred in 51% and 25% of patients in gef+C and gef arms respectively, P , 0.001. Conclusion: Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged progression free and overall survival but also increased toxicity. Pemetrexed-carboplatin-gefitinib represents a new standard first-line therapy for EGFR mutant NSCLC. Clinical trial information: CTRI/ 2016/08/007149. © 2019 American Society of Clinical Oncology. Visit abstracts.asco.org and search by abstract for disclosure information. LUNG CANCER—NON-SMALL CELL METASTATIC 9002 Oral Abstract Session, Mon, 8:00 AM-11:00 AM ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC. Suresh S. Ramalingam, Suzanne Eleanor Dahlberg, Chandra Prakash Belani, Joel N. Saltzman, Gopakumar S. Nambudiri, John McCann, Jerome D. Winegarden, Mohammed Azher Kassem, Mohamed K. Mohamed, Jan M. Rothman, Alan P. Lyss, Leora Horn, Tom Stinchcombe, Joan H. Schiller, ECOG-ACRIN Cancer Research Group; Winship Cancer Institute, Emory University, Atlanta, GA; Dana-Farber Cancer Institute, Boston, MA; Penn State Hershey Cancer Institute, Hershey, PA; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Health East Cancer Care, Woodbury, MN; Baystate Medcl Ctr, Springfield, MA; Ann Arbor Hem Onc Assocs, Ypsilanti, MI; Mt.Sinai Hosp, Chicago, IL; Cone Health Center at Wesley Long, Greensboro, NC; The Regional Cancer Center, Erie, PA; Missouri Baptist Cancer Ctr, St Louis, MO; Vanderbilt University Medical Center, Nashville, TN; Duke Cancer Institute, Durham, NC; The University of Texas Southwestern Medical Center, Dallas, TX Background: Maintenance therapy is a standard approach for advanced non-squamous NSCLC. Peme- trexed or bevacizumab are considered evidence-based options. The combination of bevacizumab and pemetrexed has been documented to improve progression-free survival (PFS). We conducted a phase 3 study to determine the optimal maintenance therapy for advanced NSCLC. Methods: Patients (pts) with advanced non-squamous NSCLC, no prior systemic therapy, and ECOG performance status 0/1 were treated with carboplatin (AUC = 6), paclitaxel (200 mg/m2) and bevacizumab (15 mg/Kg) every 3 weeks for up to 4 cycles (step 1). Patients with CR/PR/SD after 4 cycles were then randomized 1:1:1 to maintenance therapy with bevacizumab (15 mg/Kg), pemetrexed (500 mg/m2) or the combination of the two agents every 3 weeks until disease progression (step 2). The primary endpoint was overall survival (OS), defined as the time from randomization to death from any cause and censoring defined at the last date of followup. 1495 pts provided 81% power to detect a hazard ratio of 0.75 while controlling the 2- sided type I error at 0.025 for each comparison, assuming approximately 60% of those patients would be randomized. Results: We enrolled 1516 pts to step 1 (male 52%; ECOG PS 1 62%; adenocarcinoma 90%); After induction therapy, 874 (57%) pts were randomized to step 2 (median age 64 yrs; male 49%; ECOG PS 1 55%).
Load more

Recommended publications
  • Japanese Delegation of Athletics Team for Doha,Qatar 2019 27 SEP-06 OCT
    Japanese Delegation of Athletics Team For Doha,Qatar 2019 27 SEP-06 OCT IAAF World Championships in Athletics-Doha,Qatar 第 17 回 IAAF 世界陸上競技選手権大会 （ カタ ー ル ・ドー ハ ） ❶ Hirooki ARAI(L)& Kai KOBAYASHI(R) Play Back London 2017 ［プレイバック・ロンドン大会2017］ 前回の2017年ロンドン大会では男子50kmW勢が躍動。 荒井広宙が２位、小林快が3位とダブル表彰台に上り、 丸尾知司も５位に入りました。また、男子４×100ｍＲ も３位に入り、世界選手権では初のメダルを獲得。また、 サニブラウン アブデルハキームは男子100ｍで準決勝、 200ｍでは決勝に進出（７位）。日本はメダル３、入賞２ の成績を収めました。 ❷ Men’s 4×100m Relay ❸ Satoshi MARUO ❹ Abdul Hakim SANIBROWN Japanese Medalists & Prizewinners in London 2017 Silver Athlete Record Men 50kmW Hirooki ARAI ❶Left 3.41.17 Bronze Men 50kmW Kai KOBAYASHI ❶Right 3.41.19 S.TADA,S.IIZUKA, Men 4×100mR 38.04 Y.KIRYU,K.FUJIMITSU❷ 5th Men 50kmW Satoshi MARUO❸ 3.43.03 7th Men 200m Abdul Hakim SANIBROWN❹ 20.63 02 Message［メッセージ］ thletes aiming at the top of the world will be gathering in the blazing city Doha. The IAAF World Athletics Championships Doha 2019 is a great stageA for you to challenge the “power and skill” of the world, and it has an important meaning as a prelude to 2020 Tokyo Olympic Games which is quickly approaching. Expand your athletic ability you have gained through competition experiences and years of hard training here in Doha and make a huge step towards the grand stage. Along with your athletic ability, human quality is also very important. Athletics is an individual sport except for relays, but it is necessary to have Team JAPAN awareness. The consciousness of competing as a team will also enhance your human quality, and that rise helps to improve individual competitiveness. For athletes and staff, I ask you to unite by respecting each other, and have the spirit of “One for All, All for One”.
    [Show full text]
  • HEEL and TOE ONLINE the Official
    HEEL AND TOE ONLINE The official organ of the Victorian Race Walking Club 2014/2015 Number 47 25 August 2015 VRWC Preferred Supplier of Shoes, clothes and sporting accessories. Address: RUNNERS WORLD, 598 High Street, East Kew, Victoria (Melways 45 G4) Telephone: 03 9817 3503 Hours: Monday to Friday: 9:30am to 5:30pm Saturday: 9:00am to 3:00pm Website: http://www.runnersworld.com.au Facebook: http://www.facebook.com/pages/Runners-World/235649459888840 WALKER OF THE WEEK A quick word before going to my Walker of the Week. Since I am in China at the moment, I am locked out of quite a few of the resources from which I put together my weekly newsletter – facebook, twitter, dropbox, all google facilities and various other normally inoffensive websites, not to mention my own gmail account. So if your results aren't there or I haven't responded to your email, it may be that I was just not able to pick them up. Email me via [email protected] and I can rectify in next week's newsletter. And now onto business! This weeks' Walker of the Week goes to 23 year old Australian representative Dane Bird-Smith. Racing in the IAAF World Championship 20km race on Sunday morning, he overcome a mid-race bingle and an upset stomach to finish eighth, confirming his status as the next big thing in Australian walking. Dane was among a group of several walkers who crashed over a flower bed in the middle of the course at the 12km mark but he was able to regroup to claim eighth spot in a time of 1:21:37, three places better than on his world titles debut two years ago in Moscow.
    [Show full text]
  • Race Walking Judges in Olympic Games 1908-2012
    IAAF Race Walking Committee Members 1935-2015 The Council of the IAAF at a meeting In Berlin 1935 decided to appoint a special commission to study the rules of walking as well as organization questions in different countries with regard to walking. At the same time the answers to the circular letter sent out by the IAAF office concerning the Olympic walking races were to be studied by the commission which met in Paris 1.2.1936. 1935 Committee for 'Walking': Jean Genet, (FRA), Chairman. 1947 Walking Commission: Fred Blackmore, (GBR) President Ernest Holt, (GBR) Secretary Francis Guilleux (FRA) Giorgio Oberweger (ITA). B. Kopal (CZE). A. Larsen (NOR). Eric G. Linde (SWE) 1951 Walking Commission. Fred Blackmore, (GBR) President Ernest Holt, (GBR) Secretary Francis Guilleux (FRA) Bela Fehervari (HUN) Bruno Zauli, (ITA) A. M. Hagen (NOR) Eric G. Linde (SWE) Armando Libotte (SUI) 1952 Walking Commission. Fred Blackmore, (GBR) President Donald Pain, (GBR) Hon. Secretary, Francis Guilleux (FRA) Bela Fehervari (HUN) Giorgio Oberweger (ITA). A. M. Hagen (NOR) I. lonescu (ROM) Eric G. Linde (SWE) Armando Libotte (SUI) Nicolai Kalinin (USSR) 1956 Walking Commission Giorgio Oberweger, (ITA) President Donald Pain, (GBR) Hon. Secretary, Hubert Sulak (TCH) Francis Guilleux (FRA) Harold Whitlock (GBR) Bela Fehervari (HUN) A. M. Hagen (NOR) I. lonescu (ROM) Eric G. Linde (SWE) Armando Libotte (SUI) Nicolai Kalinin (USSR) 1960 Walking Commission Giorgio Oberweger, (ITA) President Donald Pain, (GBR) Hon. Secretary, Bela Fehervari (HUN) Francis Guilleux (FRA) A. M. Hagen (NOR) I. lonescu (ROM) Eric G. Linde (SWE) Armando Libotte (SUI) Hubert Sulak (CZE) Peter Stepanenko (U.S.S.R) Harold Whitlock (GBR) 1964 WALKING COMMISSION Giorgio Oberweger, (ITA) President Donald Pain, (GBR) Hon.
    [Show full text]
  • Lung Cancer—Non-Small Cell Metastatic
    LUNG CANCER—NON-SMALL CELL METASTATIC 9500 Oral Abstract Session, Fri, 8:00 AM-11:00 AM Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. Suresh S. Ramalingam, Tudor Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Michael Schenker, Reyes Bernabe Caro, Ki Hyeong Lee, Bogdan Zurawski, Clarisse Audigier-Valette, Mariano Provencio, Helena Linardou, Sang-We Kim, Hossein Borghaei, Matthew David Hellmann, Kenneth John O’Byrne, Luis G. Paz-Ares, Martin Reck, Faith Ellen Nathan, Julie R. Brahmer; Winship Cancer Institute, Emory University, Atlanta, GA; Institutul oncologic Orif Dr Ion Chiricuta and UNF Iulia Hatieganu, Cluj Napoca, Romania; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Seoul National University Bundang Hospital, Seongnam, South Korea; SF. Nectarie Oncology Center, Craiova, Romania; Hospital Universitario Virgen Del Rocio, Seville, Spain; Chungbuk National Uni- versity Hospital, Cheongju, Chungbuk, South Korea; Ambulatorium Chemioterapii, Bydgoszcz, Poland; Hopitalˆ Sainte Musse, Toulon, France; Hosp. Univ. Puerta de Hierro, Madrid, Spain; Metropolitan Hospital, Athens, Greece; Asan Medical Center, Seoul, Korea, Republic of (South); Fox Chase Cancer Center, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Princess Alexandra Hospital, Brisbane, Australia; Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense & CiberOnc, Madrid, Spain; Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Bristol-Myers Squibb, Princeton, NJ; Sidney Kimmel Com- prehensive Cancer Center at Johns Hopkins, Baltimore, MD Background: In the phase 3 CheckMate 227 Part 1 (NCT02477826; minimum follow-up, 29.3 mo), 1L NIVO + IPI significantly improved overall survival (OS) vs chemo in treatment-naive patients (pts) with aNSCLC and tumor PD-L1 expression $ 1% (primary analysis) or , 1% (pre-specified descriptive analysis).
    [Show full text]
  • GIP-Gip2019ces-1UP 1..179
    CANCERS OF THE ESOPHAGUS AND STOMACH 2 Oral Abstract Session, Thu, 2:15 PM-3:45 PM and Poster Session (Board #D12), Thu, 11:30 AM-1:00 PM and 5:30 PM-6:30 PM Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. Takashi Kojima, Kei Muro, Eric Francois, Chih-Hung Hsu, Toshikazu Moriwaki, Sung-Bae Kim, Se-Hoon Lee, Jaafar Bennouna, Ken Kato, Shen Lin, Shi-Qui Qin, Paula Ferreira, Toshihiko Doi, Antoine Adenis, Peter C. Enzinger, Manish A. Shah, Ruixue Wang, Pooja Bhagia, S. Peter Kang, Jean-Philippe Metges; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Lacassagne Anticancer Center, Nice, France; National Taiwan University Hospital, Taipei, Taiwan; University of Tsukuba, Tsukuba, Japan; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; University Hospital of Nantes, Nantes, France; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Beijing Cancer Hospital, Beijing, China; PLA Cancer Centre of Nanjing Bayi Hospital, Nanjing, China; Instituto Portuguesˆ de Oncologia Porto, Porto, Portugal; National Cancer Center Hospital East, Chiba, Japan; Centre Oscar Lambret, Lille, France; Dana-Farber Cancer Institute, Boston, MA; Weill Cornell Medicine/ New York Presbyterian Hospital, New York, NY; MSD China, Beijing, China; Merck, Kenilworth, NJ; Merck & Co., Inc., Kenilworth, NJ; Oncology & Haematology Institute, Brest University Hospital, Brest, France Background: Patients with advanced esophageal cancer after first-line chemotherapy (chemo) have a poor prognosis and limited treatment options.
    [Show full text]
  • Japanese Delegation of Athleticsteam for Moscow,RUSSIA 2013 10-18 AUG
    Japanese Delegation of AthleticsTeam for Moscow,RUSSIA 2013 10-18 AUG ⓒ PHOTO KISHIMOTO ⓒ Agence SHOT IAAF World Championships in Athletics - Moscow, RUSSIA Japan Association of Athletics Federations 2-7-1 Nishi-Shinjuku.shinjuku-ku,Tokyo,163-0717 Japan Tel 81-3-5321-6580 Official site: http://www.jaaf.or.jp/ Play Back Daegu 2011 ［ プレイ バック・テグ 2011］ 韓国・テグで行われた前回大会は室伏広治が日 本人通算４個目の金メダルを獲得。その他、男 女マラソン、男子競歩で４つの入賞を果たした。 ❷ Yukiko AKABA ❶ Koji MUROFUSHI ❸ Koichiro MORIOKA Japanese Prizewinners in World Championships Daedu 2011 テグ大会日本人入賞者 1st Athlete Mark Men Hammer Throw/ハンマー投 Koji MUROFUSHI（❶） 81.24 5th Women Marathon/マラソン Yukiko AKABA（❷） 2.29.35 6th Men 50kmW Koichiro MORIOKA（❸） 3.46.21 7th Men Marathon/マラソン Hiroyuki HORIBATA（❹） 2.11.52 8th Men 20kmW Yusuke SUZUKI（❺） 1.21.39 ❹ Hiroyuki HORIBATA ❺ Yusuke SUZUKI 02 MESSAGE ［メッセージ］ fter the London Olympics last year in August, we formed a new high Aperformance structure, and got off a start for the 2016 Rio De Janeiro Olympics at once. We can say that the 14th IAAF World Championships Moscow this August would be the primary grand stage for the new born Team Japan. When we look at athletes representing the team, it is a superb team organization composed from well experienced to the young ones, so the team is expected to get off to a very smooth and good jump start. I would like to ask the athletes not to put unnecessary strain on themselves, and to have their primary goal on setting a personal record or a season best. I hope that athletes will excel through their nine-days competition against the world’s top athletes and through experience as a member of the team.
    [Show full text]
  • Japanese Delegation of Athletics Team for London,UK 2017 04-13 AUG
    Japanese Delegation of Athletics Team For London,UK 2017 04-13 AUG ⓒ Getty Images IAAF World Championships in Athletics-London,UK 第16回 IAAF世界陸上競技選手権大会（イギリス・ロンドン） Play Back Beijing 2015 ［プレイバック・北京2015］ ２年前の北京大会では、50kmWの谷井孝行が銅メダ ルを獲得。五輪、世界選手権において、競歩では史上 初の日本人メダリストとなりました。さらに荒井広宙 が４位に入賞。女子マラソンでは、伊藤舞が７位と、 入賞３という結果を残しました。 ❹ Ryohei ARAI ❺ Ayuko SUZUKI ❶ Takayuki TANII ❻ Misaki ONISHI Japanese Prizewinners and Finalists in World Championships Beijing 2015 北京大会 日本人入賞者および決勝進出者 3rd Athlete Mark Men 50kmW Takayuki TANII ❶ 3.42.55 4th Men 50kmW Hirooki ARAI ❷ 3.43.44 7th Women Marathon Mai ITO ❸ 2.29.48 9th Men Javelin Throw Ryohei ARAI ❹ 83.07 ❸ Mai ITO 9th Women 5000m Ayuko SUZUKI ❺ 15.08.29 14th Women 5000m Misaki ONISHI ❻ 15.29.63 ❷ Hirooki ARAI MESSAGE ［メッセージ］ reat Britain, the host country of the 16th IAAF World Championships is G the birthplace of modern-day athletics. It is a great honour for athletes to perform in front of massive and passionate athletics fans at the sacred place of our beloved sport. I ask you, as a member of our National Team, to take on this prestigious stage with pride and dignity and give out all you have to achieve your goals. Your performance at the Championships represents your hard work and aspiration, and we must remind ourselves this competition leads to the 2020 Tokyo Olympic Games. I hope you to discover a hint for further raising your abilities to perform at the international level. This experience will also be inspiring and a great opportunity to build friendship with your fellow athletes from around the world. Global friendship is truly a life-time treasure and helpful in taking steps forward as an athlete.
    [Show full text]
  • A Phase III Randomized Controlled Trial of Short-Course Radiotherapy with Or
    2016 年临床肿瘤学新进展学术研讨会 1 Abstract ID: LBA2 (163254) A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC26062-22061, TROG 08.02, NCT00482677). Authors: James R. Perry, Normand Laperriere, Christopher J. O'Callaghan, Alba Ariela Brandes, Johan Menten, Claire Phillips, Michael F. Fay, Ryo Nishikawa, J. Gregory Cairncross, Wilson Roa, David Osoba, Arjun Sahgal, Hal W. Hirte, Wolfgang Wick, Florence Laigle-Donadey, Enrico Franceschi, Olivier L. Chinot, Chad Winch, Keyue Ding, Warren P. Mason; Sunnybrook Health Sciences Centre, Toronto, ON; Princess Margaret Cancer Centre, Toronto, ON; Canadian Cancer Trials Group (CTTG), Kingston, ON; Azienda USL Bellaria-Maggiore Hospital, Bologna, Italy; Department of Radiotherapy, University Hospitals Leuven and Catholic University of Leuven, Leuven, Belgium; Peter MacCallum Cancer Centre, Melbourne, Australia; Royal Brisbane Hospital, Brisbane, Australia; Saitama Medical University, Saitama, Japan; Charbonneau Cancer Institute at the University of Calgary, Calgary, AB; Cross Cancer Institute, Edmonton, AB; QOL Consulting, West Vancouver, BC; Odette Cancer Centre, Toronto, ON; Juravinski Cancer Centre, Hamilton, ON; Neurology Clinic, Heidelberg, Germany; APHP Service de Neuro-Oncologie, Paris, France; Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy; Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France; Canadian Cancer Trials Group, Queen's University, Kingston, ON; Princess Margaret Hospital, Toronto, ON Background: The EORTC (26981-22981)/NCIC CTG (CE.3) RCT in newly diagnosed glioblastoma (GB) showed increased overall survival (OS) with concomitant and adjuvant temozolomide (TMZ) added to radiotherapy (RT). Pts were 18-71 (median 56) years; however a trend of decreasing benefit from the addition of TMZ with increasing age was noted.
    [Show full text]
  • HEEL and TOE ONLINE the Official Organ of The
    HEEL AND TOE ONLINE The official organ of the Victorian Race Walking Club 2014/2015 Number 47 25 August 2015 VRWC Preferred Supplier of Shoes, clothes and sporting accessories. Address: RUNNERS WORLD, 598 High Street, East Kew, Victoria (Melways 45 G4) Telephone: 03 9817 3503 Hours: Monday to Friday: 9:30am to 5:30pm Saturday: 9:00am to 3:00pm Website: http://www.runnersworld.com.au Facebook: http://www.facebook.com/pages/Runners-World/235649459888840 WALKER OF THE WEEK A quick word before going to my Walker of the Week. Since I am in China at the moment, I am locked out of quite a few of the resources from which I put together my weekly newsletter – facebook, twitter, dropbox, all google facilities and various other normally inoffensive websites, not to mention my own gmail account. So if your results aren't there or I haven't responded to your email, it may be that I was just not able to pick them up. Email me via [email protected] and I can rectify in next week's newsletter. And now onto business! This weeks' Walker of the Week goes to 23 year old Australian representative Dane Bird-Smith. Racing in the IAAF World Championship 20km race on Sunday morning, he overcome a mid-race bingle and an upset stomach to finish eighth, confirming his status as the next big thing in Australian walking. Dane was among a group of several walkers who crashed over a flower bed in the middle of the course at the 12km mark but he was able to regroup to claim eighth spot in a time of 1:21:37, three places better than on his world titles debut two years ago in Moscow.
    [Show full text]
  • HEEL and TOE ONLINE the Official Organ of the Victorian Race Walking Club 2018/2019 Number 19 5 February 2019 VRWC Preferred
    HEEL AND TOE ONLINE The official organ of the Victorian Race Walking Club 2018/2019 Number 19 5 February 2019 VRWC Preferred Supplier of Shoes, clothes and sporting accessories. Address: RUNNERS WORLD, 598 High Street, East Kew, Victoria (Melways 45 G4) Telephone: 03 9817 3503 Hours: Monday to Friday: 9:30am to 5:30pm Saturday: 9:00am to 3:00pm Website: http://www.runnersworld.com.au Facebook: http://www.facebook.com/pages/Runners-World/235649459888840 WALKING FIGHTS FOR ITS SURVIVAL AGAIN Alas, I have the worst possible news this week and the cartoon above, from Stefano La Sorda of the marcia.com facebook page sums it up well. The final fatal shots have been fired at the 50km. Stefano might well ask – who are the killers? It is time to name names. The process seems clearly to have been instigated and supported by two of the top people in the IAAF, namely Sebastian Coe (IAAF President) and Paul Hardy (IAAF Competitions Director). Their hatchet man, who has driven the process for them, is Luis Saladie (IAAF Head of Competition Management) Their willing accomplices have been the majority of the IAAF Race Walking Committee, led by Maurizio DaMilano. Maurizio DAMILANO ITA (Chairman) Khaled AMARA TUN Tim BERRETT CAN Jean-Pierre DAHM FRA Maryanne DANIEL USA Fumio IMAMURA JPN Robert KORZENIOWSKI POL Peter MARLOW GBR Jefferson PEREZ ECU Miguel Angel RODRIGUEZ MEX Jane SAVILLE AUS Shande YANG CHN 1 There are a couple of exceptions on the committee, who have continuously pushed back against the distance changes, but they have been and continue to be in the minority.
    [Show full text]